September 24, 2021 -- Twist Bioscience announced it is collaborating with DeepCDR to apply deep-learning algorithms to Twist's antibody discovery and optimization capabilities.
DeepCDR's algorithms can generate large panels of fully human antibody sequences. Using these sequences, Twist has built multiple fully human synthetic antibody libraries, specifically a hypermutated single-chain, fragment-variable library and a new coronavirus-specific single-chain, fragment-variable library, company officials said.
Twist's platform uses a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip, the company said.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: